Advances in immunosuppression for renal transplantation.
The development of immunosuppressants with minimal adverse and nephrotoxic effects is important to improve outcomes, such as acute and chronic antibody-mediated rejection, after organ transplantation. In addition, the application of expanded criteria for donors and transplantation in immunized patients necessitates the development of new therapies. Drug development over the past 10 years has generally been disappointing, but several new promising compounds have been or are being developed to prevent acute and chronic transplant rejection. In this Review, we report on several compounds that have been developed to remove allogenic T cells and/or to inhibit T-cell activation. We also discuss compounds that interfere with antibody-mediated rejection.
Durrbach
Antoine
A
Nephrology and Transplantation Department, Hopital Bicetre, UMR U542 INSERM/University Paris-Sud XI, Paris, France.
Francois
Helene
H
Beaudreuil
Severine
S
Jacquet
Antoine
A
Charpentier
Bernard
B
D000818:Animals; D005260:Female; D005544:Forecasting; D006084:Graft Rejection; D006085:Graft Survival; D000882:Haplorhini; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods / Q000639:trends*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000379:methods; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D017751:Safety Management; D016019:Survival Analysis; D014181:Transplantation Immunology / Q000187:drug effects* / Q000502:physiology; D023001:Transplantation Tolerance / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D007166:Immunosuppressive Agents